116 related articles for article (PubMed ID: 38279433)
1. GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells.
Zhang X; Zhang L; Wang B; Zhang X; Gu L; Guo K; Zhang X; Zhou Z
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):221-225. PubMed ID: 38279433
[TBL] [Abstract][Full Text] [Related]
2. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway.
Zhao H; Wang L; Wei R; Xiu D; Tao M; Ke J; Liu Y; Yang J; Hong T
Diabetes Obes Metab; 2014 Sep; 16(9):850-60. PubMed ID: 24641303
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving β-catenin.
Wu X; Li S; Xue P; Li Y
Exp Cell Res; 2017 Nov; 360(2):281-291. PubMed ID: 28919123
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K/Akt pathway in keratinocytes.
Nagae K; Uchi H; Morino-Koga S; Tanaka Y; Oda M; Furue M
Diabetes Res Clin Pract; 2018 Dec; 146():155-161. PubMed ID: 30367901
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide Inhibits the Apoptosis of MC3T3-E1 Cells Induced by Serum Deprivation through cAMP/PKA/β-Catenin and PI3K/AKT/GSK3β Signaling Pathways.
Wu X; Li S; Xue P; Li Y
Mol Cells; 2018 Mar; 41(3):234-243. PubMed ID: 29463067
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways.
Shi L; Ji Y; Jiang X; Zhou L; Xu Y; Li Y; Jiang W; Meng P; Liu X
Cardiovasc Diabetol; 2015 Feb; 14():18. PubMed ID: 25855361
[TBL] [Abstract][Full Text] [Related]
7. Liraglutide inhibits the apoptosis of human nucleus pulposus cells induced by high glucose through PI3K/Akt/caspase-3 signaling pathway.
Ming-Yan Y; Jing Z; Shu-Qin G; Xiao-Liang B; Zhi-Hong L; Xue Z
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31383790
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide Attenuates Myocardial Ischemia/Reperfusion Injury Through the Inhibition of Necroptosis by Activating GLP-1R/PI3K/Akt Pathway.
Zhou G; Wu H; Yang J; Ye M; Liu D; Li Y; Zhang D; Zhang J; Yang Q; Liu Y
Cardiovasc Toxicol; 2023 Apr; 23(3-4):161-175. PubMed ID: 36934206
[TBL] [Abstract][Full Text] [Related]
9. GLP-1RA promotes brown adipogenesis of C3H10T1/2 mesenchymal stem cells via the PI3K-AKT-mTOR signaling pathway.
Wang X; Chen J; Rong C; Pan F; Zhao X; Hu Y
Biochem Biophys Res Commun; 2018 Dec; 506(4):976-982. PubMed ID: 30404729
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4/ROS/VEGF pathway.
Liu ZZ; Duan XX; Yuan MC; Yu J; Hu X; Han X; Lan L; Liu BW; Wang Y; Qin JF
Life Sci; 2022 Apr; 294():120370. PubMed ID: 35124000
[TBL] [Abstract][Full Text] [Related]
11. Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer.
Kanda R; Hiraike H; Wada-Hiraike O; Ichinose T; Nagasaka K; Sasajima Y; Ryo E; Fujii T; Osuga Y; Ayabe T
BMC Cancer; 2018 Jun; 18(1):657. PubMed ID: 29907137
[TBL] [Abstract][Full Text] [Related]
12. Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells.
Zhao HJ; Jiang X; Hu LJ; Yang L; Deng LD; Wang YP; Ren ZP
J Mol Endocrinol; 2020 Feb; 64(2):103-113. PubMed ID: 31855560
[TBL] [Abstract][Full Text] [Related]
13. GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner.
Liu J; Yang K; Xiao W; Le Y; Lang S; Zhang J; Wei R; Yang J; Hong T
Peptides; 2018 Aug; 106():83-90. PubMed ID: 30003931
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.
Foer D; Amin T; Nagai J; Tani Y; Feng C; Liu T; Newcomb DC; Lai J; Hayashi H; Snyder WE; McGill A; Lin A; Laidlaw TM; Niswender KD; Boyce JA; Cahill KN
J Immunol; 2023 Dec; 211(12):1806-1813. PubMed ID: 37870292
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Liraglutide on Lung Cancer and Its Potential Protective Effect on High Glucose-Induced Lung Senescence and Oxidative Damage.
Pu Z; Yang Y; Qin S; Li X; Cui C; Chen W
Front Biosci (Landmark Ed); 2023 Oct; 28(10):259. PubMed ID: 37919054
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation.
Barale C; Buracco S; Cavalot F; Frascaroli C; Guerrasio A; Russo I
Thromb Haemost; 2017 Jun; 117(6):1115-1128. PubMed ID: 28405672
[TBL] [Abstract][Full Text] [Related]
17. Liraglutide Promotes the Osteogenic Differentiation in MC3T3-E1 Cells via Regulating the Expression of Smad2/3 Through PI3K/Akt and Wnt/β-Catenin Pathways.
Gao L; Li SL; Li YK
DNA Cell Biol; 2018 Dec; 37(12):1031-1043. PubMed ID: 30403540
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like Peptide-1 Analogues Inhibit Proliferation and Increase Apoptosis of Human Prostate Cancer Cells in vitro.
Li XN; Bu HM; Ma XH; Lu S; Zhao S; Cui YL; Sun J
Exp Clin Endocrinol Diabetes; 2017 Feb; 125(2):91-97. PubMed ID: 28008585
[No Abstract] [Full Text] [Related]
19. Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R/Akt/GSK3β signaling.
Shu X; Zhang Y; Li M; Huang X; Yang Y; Zeng J; Zhao Y; Wang X; Zhang W; Ying Y
Neuropharmacology; 2019 Jul; 153():1-12. PubMed ID: 31015047
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide preserves CD34
Sforza A; Vigorelli V; Rurali E; Perrucci GL; Gambini E; Arici M; Metallo A; Rinaldi R; Fiorina P; Barbuti A; Raucci A; Sacco E; Rocchetti M; Pompilio G; Genovese S; Vinci MC
Cardiovasc Diabetol; 2022 Apr; 21(1):51. PubMed ID: 35397526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
